General

WOIPPY, FRANCE, July 16, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to Interlux OÜ (https://www.linkedin.com/company/interlux-estonia/ ) the rights to promote and commercialize ABLD assays and software […]

Management of the APOBEC Mutations through the DeepChek-HIV Proviral DNA Genotyping Assays & Software OVERVIEW & USERS EXPERIENCE Webinar from Thursday June 13, 2024 – 4pm CEST

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce the involvement of its entire team to support fight against Respiratory Syncytial Virus (RSV). Even if RSV is a common respiratory virus that usually causes mild, cold-like symptoms,

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is participating to the European Meeting on HIV & Hepatitis (AME) 2024 held in Barcelona. ABL Diagnostics, alone and with partners, will showcase several disruptive scientific communications about the use of its

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the official appointment of the company and its exclusive distributor, Laborama Co. Ltd., for the provision of Next Generation Sequencing (“NGS”) solutions to the National Laboratory for

Barcelona, Spain, 29 April 2024 – MGI Tech (MGI), a company committed to building core tools and technology to lead life science, today introduced the latest addition to its range of sequencers, the portable and easy-to-use DNBSEQ-E25 platform, for the European and African market. In addition, the company showcased its current offering of laboratory automation

ABL DIAGNOSTICS (ABLD) has announced the signing of a liquidity contract with ALLInvest Securities, effective from the morning of 24.04.2024. ABL Diagnostics SA (EPA:ABLD)WOIPPY, FRANCE, April 24, 2024 /EINPresswire.com/ — ABL DIAGNOSTICS (ticker ABLD, ISIN FR001400AHX6), Euronext Compartment B, announces that it has signed a liquidity contract with ALLInvest Securities, effective from the morning of

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, is pleased to announce today the execution of a non-exclusive distribution agreement to confer to Medline Industries, LP (www.medline.com) the rights to promote and

Newburyport (MA, USA) – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics S.A. (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of a new agreement with VELA Diagnostics USA Inc. to expand the scope of services announced

Woippy (France) – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is announcing today the execution of a distribution agreement conferring to PALEX (https://www.palexmedical.com/) the rights to offer ABL Diagnostics products to laboratories in Spain. The collaboration will be carried out through a